Siirry pääsisältöön
Käyttämääsi selainta ei enää tueta – lue lisää.
Ylin-
Alin-
Vaihto-
Ylin-
Alin-
Vaihto-
Ylin-
Alin-
Vaihto-
Ylin-
Alin-
Vaihto-
Ylin-
Alin-
Vaihto-
Ylin-
Alin-
Vaihto-
2025 Q4 -tulosraportti

Vain PDF

21 päivää sitten

Tarjoustasot

NorwayOslo Børs
Määrä
Osto
-
Myynti
Määrä
-

Viimeisimmät kaupat

AikaHintaMääräOstajaMyyjä
40--
900--
1 000--
500--
5 745--

Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.

Välittäjätilasto

Dataa ei löytynyt

Yhtiötapahtumat

Datan lähde: FactSet, Quartr
Seuraava tapahtuma
2026 Q2 -tulosraportti
31.8.
Menneet tapahtumat
2025 Q4 -tulosraportti
15.4.
2025 Q2 -tulosraportti
28.8.2025
2024 Q4 -tulosraportti
10.4.2025
2024 Q2 -tulosraportti
29.8.2024
2023 Q4 -tulosraportti
25.4.2024

Foorumi

Liity keskusteluun Nordnet Socialissa
Kirjaudu
  • 50 min sitten
    50 min sitten
    Neste 5kr📉📉📉📉📉📉📉⬇️⬇️⬇️😂😂😂🤦🏿🤦🏿🤦🏿🤦🏿
    24 min sitten
    ·
    24 min sitten
    ·
    Such a nice portfolio😅 you and pumba, you know
  • 1 t sitten
    ·
    1 t sitten
    ·
    WHY CIRCIO CANNOT BE COMPARED TO ANYTHING ELSE ON THE STOCK EXCHANGE 🧬⚡ There's a lot of noise (and yapping) on the forum now from people who are annoyed by red days, price volatility, and that things "don't go in a straight line". Let's clear up the biggest misunderstanding about this case: Circio is not a normal A4 stock. What we are in here, is in practice a pure Venture Capital (VC) case that coincidentally is available on an open stock exchange for retail investors. What does that actually mean? Normally, platform companies in this phase – with exponential technology like circVec, international heavyweight collaborations (Acuitas) and massive R&D – are hidden away in closed PE or VC funds. Why? Because value creation in deep biotech is never linear. Traditional investors expect a stock to rise nicely and orderly by 2 % after a "good quarterly report". That's not how this game works. Biology doesn't care about trading graphs. In a VC case, it shakes. It goes sideways. The price is manipulated by traders looking for dimes. People lose patience and throw in the cards because they get bored. But when the repricing in such cases first comes, it doesn't happen gradually. It happens with a bang. • A breakthrough in the data. • A validation from Big Pharma. • A licensing agreement at a conference like ASGCT. When the substance hits the market, the price gaps up – and those who tried to be smart by trading in and out, are left on the platform. Bottom line: Either you understand the asymmetry and potential in owning a piece of a global gene therapy platform, or you should buy index funds. It is meaningless to spend time analyzing small, daily price movements when the company is preparing to turn the entire RNA industry upside down. Let traders yap about the noise. We focus on the substance. We know what we own. ♟️🧱🍷
    8 min sitten
    ·
    8 min sitten
    ·
    💯
  • 1 t sitten
    ·
    1 t sitten
    ·
    Just a thought, but if I don't buy warrants, wouldn't I still have bought CRNA cheaply when the warrants are exercised, because for example if the price is then at 10kr and everyone with warrants exercises at 8kr8will not the price automatically fall to around the 8 area due to all those trades at 8kr?
    18 min sitten
    ·
    18 min sitten
    ·
    Your way of thinking applies better to a regular share issue; this becomes a bit more complex.
  • 1 t sitten
    ·
    1 t sitten
    ·
    There is probably no doubt that the management hopes for full redemption of TR to further strengthen itself financially. Especially considering that the repair issue at 10:80 lapsed when the share price was down. There is probably also no doubt that it is in the company's best interest to raise as much capital as possible to stand on its own feet in further research and development, as well as to make itself more robust towards potential stakeholders. The question is who can afford to redeem TR. It must be assumed that the larger players have already positioned themselves, or plan to do so, and have their finances ready. As a «small shareholder», most are probably more price-sensitive and in the short term benefit from the lowest possible price to be able to exercise as many TR as possible. Even though the plan is set with dates and guidelines for implementation, the game is still unpredictable here and now. When the exercise price is set in a couple of weeks, we will know more. But, the joker remains unanswered, namely if and when, the management might release price-driving news that could affect an individual's financial ability to redeem TR.
    3 min sitten
    ·
    3 min sitten
    ·
    It would greatly surprise me if the company does not provide all positive information they can give in the period 8th to 22nd May. This is to bring in a decent amount of TR money. There must be information that triggers buying interest above 10.80 for continued price increase. If this doesn't happen, my lottery ticket is that we fall to both 7 and 5 in the dip. Anything can happen here!
  • 2 t sitten · Muokattu
    ·
    2 t sitten · Muokattu
    ·
    I'm trying my best to understand this with the current value per share. Is it so that it is kept down until warrants must be exercised at the value set on May 22? So is it an advantage to get the cheapest possible exercise per warrant?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, ​​eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.

Uutiset

AI
Viimeisin
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.

Tuotteita joiden kohde-etuutena tämä arvopaperi

2025 Q4 -tulosraportti

Vain PDF

21 päivää sitten

Uutiset

AI
Viimeisin
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.

Foorumi

Liity keskusteluun Nordnet Socialissa
Kirjaudu
  • 50 min sitten
    50 min sitten
    Neste 5kr📉📉📉📉📉📉📉⬇️⬇️⬇️😂😂😂🤦🏿🤦🏿🤦🏿🤦🏿
    24 min sitten
    ·
    24 min sitten
    ·
    Such a nice portfolio😅 you and pumba, you know
  • 1 t sitten
    ·
    1 t sitten
    ·
    WHY CIRCIO CANNOT BE COMPARED TO ANYTHING ELSE ON THE STOCK EXCHANGE 🧬⚡ There's a lot of noise (and yapping) on the forum now from people who are annoyed by red days, price volatility, and that things "don't go in a straight line". Let's clear up the biggest misunderstanding about this case: Circio is not a normal A4 stock. What we are in here, is in practice a pure Venture Capital (VC) case that coincidentally is available on an open stock exchange for retail investors. What does that actually mean? Normally, platform companies in this phase – with exponential technology like circVec, international heavyweight collaborations (Acuitas) and massive R&D – are hidden away in closed PE or VC funds. Why? Because value creation in deep biotech is never linear. Traditional investors expect a stock to rise nicely and orderly by 2 % after a "good quarterly report". That's not how this game works. Biology doesn't care about trading graphs. In a VC case, it shakes. It goes sideways. The price is manipulated by traders looking for dimes. People lose patience and throw in the cards because they get bored. But when the repricing in such cases first comes, it doesn't happen gradually. It happens with a bang. • A breakthrough in the data. • A validation from Big Pharma. • A licensing agreement at a conference like ASGCT. When the substance hits the market, the price gaps up – and those who tried to be smart by trading in and out, are left on the platform. Bottom line: Either you understand the asymmetry and potential in owning a piece of a global gene therapy platform, or you should buy index funds. It is meaningless to spend time analyzing small, daily price movements when the company is preparing to turn the entire RNA industry upside down. Let traders yap about the noise. We focus on the substance. We know what we own. ♟️🧱🍷
    8 min sitten
    ·
    8 min sitten
    ·
    💯
  • 1 t sitten
    ·
    1 t sitten
    ·
    Just a thought, but if I don't buy warrants, wouldn't I still have bought CRNA cheaply when the warrants are exercised, because for example if the price is then at 10kr and everyone with warrants exercises at 8kr8will not the price automatically fall to around the 8 area due to all those trades at 8kr?
    18 min sitten
    ·
    18 min sitten
    ·
    Your way of thinking applies better to a regular share issue; this becomes a bit more complex.
  • 1 t sitten
    ·
    1 t sitten
    ·
    There is probably no doubt that the management hopes for full redemption of TR to further strengthen itself financially. Especially considering that the repair issue at 10:80 lapsed when the share price was down. There is probably also no doubt that it is in the company's best interest to raise as much capital as possible to stand on its own feet in further research and development, as well as to make itself more robust towards potential stakeholders. The question is who can afford to redeem TR. It must be assumed that the larger players have already positioned themselves, or plan to do so, and have their finances ready. As a «small shareholder», most are probably more price-sensitive and in the short term benefit from the lowest possible price to be able to exercise as many TR as possible. Even though the plan is set with dates and guidelines for implementation, the game is still unpredictable here and now. When the exercise price is set in a couple of weeks, we will know more. But, the joker remains unanswered, namely if and when, the management might release price-driving news that could affect an individual's financial ability to redeem TR.
    3 min sitten
    ·
    3 min sitten
    ·
    It would greatly surprise me if the company does not provide all positive information they can give in the period 8th to 22nd May. This is to bring in a decent amount of TR money. There must be information that triggers buying interest above 10.80 for continued price increase. If this doesn't happen, my lottery ticket is that we fall to both 7 and 5 in the dip. Anything can happen here!
  • 2 t sitten · Muokattu
    ·
    2 t sitten · Muokattu
    ·
    I'm trying my best to understand this with the current value per share. Is it so that it is kept down until warrants must be exercised at the value set on May 22? So is it an advantage to get the cheapest possible exercise per warrant?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, ​​eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.

Tarjoustasot

NorwayOslo Børs
Määrä
Osto
-
Myynti
Määrä
-

Viimeisimmät kaupat

AikaHintaMääräOstajaMyyjä
40--
900--
1 000--
500--
5 745--

Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.

Välittäjätilasto

Dataa ei löytynyt

Yhtiötapahtumat

Datan lähde: FactSet, Quartr
Seuraava tapahtuma
2026 Q2 -tulosraportti
31.8.
Menneet tapahtumat
2025 Q4 -tulosraportti
15.4.
2025 Q2 -tulosraportti
28.8.2025
2024 Q4 -tulosraportti
10.4.2025
2024 Q2 -tulosraportti
29.8.2024
2023 Q4 -tulosraportti
25.4.2024

Tuotteita joiden kohde-etuutena tämä arvopaperi

2025 Q4 -tulosraportti

Vain PDF

21 päivää sitten

Uutiset

AI
Viimeisin
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.

Yhtiötapahtumat

Datan lähde: FactSet, Quartr
Seuraava tapahtuma
2026 Q2 -tulosraportti
31.8.
Menneet tapahtumat
2025 Q4 -tulosraportti
15.4.
2025 Q2 -tulosraportti
28.8.2025
2024 Q4 -tulosraportti
10.4.2025
2024 Q2 -tulosraportti
29.8.2024
2023 Q4 -tulosraportti
25.4.2024

Tuotteita joiden kohde-etuutena tämä arvopaperi

Foorumi

Liity keskusteluun Nordnet Socialissa
Kirjaudu
  • 50 min sitten
    50 min sitten
    Neste 5kr📉📉📉📉📉📉📉⬇️⬇️⬇️😂😂😂🤦🏿🤦🏿🤦🏿🤦🏿
    24 min sitten
    ·
    24 min sitten
    ·
    Such a nice portfolio😅 you and pumba, you know
  • 1 t sitten
    ·
    1 t sitten
    ·
    WHY CIRCIO CANNOT BE COMPARED TO ANYTHING ELSE ON THE STOCK EXCHANGE 🧬⚡ There's a lot of noise (and yapping) on the forum now from people who are annoyed by red days, price volatility, and that things "don't go in a straight line". Let's clear up the biggest misunderstanding about this case: Circio is not a normal A4 stock. What we are in here, is in practice a pure Venture Capital (VC) case that coincidentally is available on an open stock exchange for retail investors. What does that actually mean? Normally, platform companies in this phase – with exponential technology like circVec, international heavyweight collaborations (Acuitas) and massive R&D – are hidden away in closed PE or VC funds. Why? Because value creation in deep biotech is never linear. Traditional investors expect a stock to rise nicely and orderly by 2 % after a "good quarterly report". That's not how this game works. Biology doesn't care about trading graphs. In a VC case, it shakes. It goes sideways. The price is manipulated by traders looking for dimes. People lose patience and throw in the cards because they get bored. But when the repricing in such cases first comes, it doesn't happen gradually. It happens with a bang. • A breakthrough in the data. • A validation from Big Pharma. • A licensing agreement at a conference like ASGCT. When the substance hits the market, the price gaps up – and those who tried to be smart by trading in and out, are left on the platform. Bottom line: Either you understand the asymmetry and potential in owning a piece of a global gene therapy platform, or you should buy index funds. It is meaningless to spend time analyzing small, daily price movements when the company is preparing to turn the entire RNA industry upside down. Let traders yap about the noise. We focus on the substance. We know what we own. ♟️🧱🍷
    8 min sitten
    ·
    8 min sitten
    ·
    💯
  • 1 t sitten
    ·
    1 t sitten
    ·
    Just a thought, but if I don't buy warrants, wouldn't I still have bought CRNA cheaply when the warrants are exercised, because for example if the price is then at 10kr and everyone with warrants exercises at 8kr8will not the price automatically fall to around the 8 area due to all those trades at 8kr?
    18 min sitten
    ·
    18 min sitten
    ·
    Your way of thinking applies better to a regular share issue; this becomes a bit more complex.
  • 1 t sitten
    ·
    1 t sitten
    ·
    There is probably no doubt that the management hopes for full redemption of TR to further strengthen itself financially. Especially considering that the repair issue at 10:80 lapsed when the share price was down. There is probably also no doubt that it is in the company's best interest to raise as much capital as possible to stand on its own feet in further research and development, as well as to make itself more robust towards potential stakeholders. The question is who can afford to redeem TR. It must be assumed that the larger players have already positioned themselves, or plan to do so, and have their finances ready. As a «small shareholder», most are probably more price-sensitive and in the short term benefit from the lowest possible price to be able to exercise as many TR as possible. Even though the plan is set with dates and guidelines for implementation, the game is still unpredictable here and now. When the exercise price is set in a couple of weeks, we will know more. But, the joker remains unanswered, namely if and when, the management might release price-driving news that could affect an individual's financial ability to redeem TR.
    3 min sitten
    ·
    3 min sitten
    ·
    It would greatly surprise me if the company does not provide all positive information they can give in the period 8th to 22nd May. This is to bring in a decent amount of TR money. There must be information that triggers buying interest above 10.80 for continued price increase. If this doesn't happen, my lottery ticket is that we fall to both 7 and 5 in the dip. Anything can happen here!
  • 2 t sitten · Muokattu
    ·
    2 t sitten · Muokattu
    ·
    I'm trying my best to understand this with the current value per share. Is it so that it is kept down until warrants must be exercised at the value set on May 22? So is it an advantage to get the cheapest possible exercise per warrant?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, ​​eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.

Tarjoustasot

NorwayOslo Børs
Määrä
Osto
-
Myynti
Määrä
-

Viimeisimmät kaupat

AikaHintaMääräOstajaMyyjä
40--
900--
1 000--
500--
5 745--

Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.

Välittäjätilasto

Dataa ei löytynyt
© 2026 Nordnet Bank AB.
Nordnet | Alvar Aallon katu 5 C, 3. krs | FI-00100 Helsinki